targeted-therapy | Media Room

Press Release Nov 15, 2021

Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform

Researchers Find a Pathway That Leads to Resistance of Aggressive Brain Tumor Treatment

Dartmouth scientists found a therapeutic approach that should prevent the development of resistance to targeted anti-tumor drugs in gliomas

Vascular BioSciences Awarded $1.2 Million Contract from the NHLBI's VITA Program to Develop CAR Peptide Therapeutic Adjuvant for PAH Targeted Therapy

VBS announced the award of a $1.2 million, milestone-based, 3-year contract from the National Heart Lung Blood Institute (NHLBI) of the National Institutes of Health (NIH) to expedite the development of CAR therapeutic peptide pulmonary hypertension